Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Travere Therapeutics (TVTX – Research Report), Meridian Bioscience (VIVO – Research Report) and Neurocrine (NBIX – Research Report).
Travere Therapeutics (TVTX)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Travere Therapeutics today and set a price target of $42.00. The company’s shares closed last Friday at $27.83.
According to TipRanks.com, Arce is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Travere Therapeutics with a $41.40 average price target, a 65.0% upside from current levels. In a report issued on July 25, SVB Securities also maintained a Buy rating on the stock with a $42.00 price target.
See the top stocks recommended by analysts >>
Meridian Bioscience (VIVO)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Hold rating on Meridian Bioscience, with a price target of $34.00. The company’s shares closed last Friday at $32.50, close to its 52-week high of $34.38.
According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Meridian Bioscience is a Hold with an average price target of $34.00.
Neurocrine (NBIX)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Neurocrine today and set a price target of $140.00. The company’s shares closed last Friday at $104.04, close to its 52-week high of $108.02.
According to TipRanks.com, Fein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurocrine with a $112.27 average price target, which is a 17.7% upside from current levels. In a report issued on July 29, Robert W. Baird also maintained a Buy rating on the stock with a $117.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TVTX:
- H.C. Wainwright Sticks to Their Buy Rating for Gritstone Oncology (GRTS)
- H.C. Wainwright Sticks to Its Buy Rating for Aldeyra Therapeutics (ALDX)
- H.C. Wainwright Reaffirms Their Buy Rating on Paratek Pharmaceuticals (PRTK)
- H.C. Wainwright Sticks to Their Buy Rating for Cardiff Oncology (CRDF)
- H.C. Wainwright Sticks to Its Buy Rating for Aeterna Zentaris (AEZS)
